Affiliation:
1. Department of Orthopaedics, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong
Pharmaceutical University; No. 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong Province, China
2. Sun
Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107, YanJiang Road, Haizhu District, Guangzhou, China
Abstract
Background:
Benefiting from in-depth research into stem cells, extracellular vesicles (EVs),
which are byproducts of cells and membrane-wrapped microvesicles (30-120 nm) containing lipids, proteins,
and nucleic acids, may cast light on the research and development of therapeutics capable of improving
the neurological recovery of spinal cord injury (SCI) animals. However, the mechanistic modes
of action for EVs in alleviating the lesion size of SCI remain to be solved, thus presenting a tremendous
gap existing in translation from the laboratory to the clinic.
Objective:
The purpose of this minireview was to cover a wide range of basic views on EVs involved in
SCI treatment, including the effects of EVs on the pathogenesis, treatment, and diagnosis of spinal cord
injury.
Methods:
We searched databases (i.e., PubMed, Web of Science, Scopus, Medline, and EMBASE) and
acquired all accessible articles published in the English language within five years. Studies reporting laboratory
applications of EVs in the treatment of SCI were included and screened to include studies presenting
relevant molecular mechanisms.
Results:
This review first summarized the basic role of EVs in cell communication, cell death, inflammatory
cascades, scar formation, neuronal regrowth, and angiogenesis after SCI, thereby providing insights
into neuroprotection and consolidated theories for future clinical application of EVs.
Conclusion:
EVs participate in an extremely wide range of cell activities, play a critical role in cell communication
centring neurons, and are considered potential therapies and biomarkers for SCI. miRNAs are
the most abundant nucleic acids shipped by EVs and effluent cytokines, and they may represent important
messengers of EVs and important factors in SCI treatment.
Publisher
Bentham Science Publishers Ltd.
Subject
General Medicine,Medicine (miscellaneous)
Reference126 articles.
1. Singh A.; Tetreault L.; Kalsi-Ryan S.; Nouri A.; Fehlings M.G.; Global prevalence and incidence of traumatic spinal cord injury. Clin Epidemiol 2014,6,309-331
2. Moons W.G.; Shields G.S.; Anxiety, not anger, induces inflammatory activity: An avoidance/approach model of immune system activation. Emotion 2015,15(4),463-476
3. Rodrigues L.F.; Moura-Neto V.; E Spohr TCLS. Biomarkers in spinal cord injury: From prognosis to treatment. Mol Neurobiol 2018,55(8),6436-6448
4. Hamid R.; Averbeck M.A.; Chiang H.; Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol 2018,36(10),1517-1527
5. Charles E.D.; Fine P.R.; Stover S.L.; Wood T.; Lott A.F.; Kronenfeld J.; The costs of spinal cord injury. Paraplegia 1978,15(4),302-310